Form 4: BeOne Medicines Director Sells Over 2,000 ADSs Under Pre-Arranged Trading Plan

Xiaodong Wang, a Director and 10% Owner of BeOne Medicines Ltd., executed sales of 2,007 American Depositary Shares (ADS) on June 24, 2025, through a Rule 10b5-1 trading plan.

Summary

• Xiaodong Wang, identified as a Director, 10% Owner, and Chair of the Scientific Advisory Board for BeOne Medicines Ltd. (ONC), reported sales of American Depositary Shares (ADS).
• On June 24, 2025, Mr. Wang sold a total of 2,007 American Depositary Shares (ADS) in four separate transactions.
• The sales were executed at weighted average prices ranging from $263.50 to $267.81 per ADS.
• Specifically, 300 ADSs were sold at $263.50, 1,100 ADSs at $265.3525, 507 ADSs at $266.5653, and 100 ADSs at $267.81.
• Each American Depositary Share represents 13 Ordinary Shares of BeOne Medicines Ltd.
• The sales were conducted pursuant to a Rule 10b5-1 trading plan that was adopted on August 12, 2024.
• Following these transactions, Mr. Wang directly holds 0 American Depositary Shares.
• Mr. Wang's beneficial ownership of Ordinary Shares includes 5,154,770 directly held, 1,025,063 indirectly held by a family trust (beneficial ownership disclaimed), 3,953,100 indirectly held by Wang Investment LLC (beneficial ownership disclaimed), and 50 indirectly held by his spouse (beneficial ownership disclaimed).

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider selling can be perceived negatively, the fact that it was executed under a pre-arranged 10b5-1 plan mitigates concerns that it's based on new, adverse information. It's a planned diversification or liquidity event.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, which indicates the transactions were scheduled in advance and not based on new, non-public information, promoting transparency.
• The reporting person, Xiaodong Wang, continues to hold a significant number of Ordinary Shares directly and indirectly, despite the ADS sales.

Negatives

• Insider selling, even when pre-planned, can sometimes be perceived negatively by the market as it may suggest that the insider believes the stock has reached a favorable selling point or that future growth prospects are limited.
• The direct holding of American Depositary Shares by the reporting person has been reduced to zero following these transactions.

Risks

• Potential negative market perception: Despite being a pre-planned sale, insider selling can sometimes lead to negative investor sentiment or speculation, potentially putting downward pressure on the stock price.
• Liquidity impact: While minor, the sale of a significant number of ADSs by a key insider could theoretically impact market liquidity for the shares.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This filing is a routine insider transaction report and does not provide information directly related to broader industry trends or competitive landscape beyond the company's stock performance.

Related Party Transactions

• The reporting person disclaims beneficial ownership of 1,025,063 Ordinary Shares held by a family trust, 3,953,100 Ordinary Shares held by Wang Investment LLC, and 50 Ordinary Shares held by his spouse, although these are considered indirect beneficial holdings.

Stakeholder Impact

• Shareholders: The sale by a key insider, even if pre-planned, could lead to minor concerns about management's confidence, potentially influencing short-term stock price movements. However, the pre-planned nature reduces the severity of this impact.

Key Dates

Recommendation

Keywords

BeOne Medicines, ONC, Form 4, Insider Trading, Stock Sale, Director, 10b5-1 Plan, American Depositary Shares, Beneficial Ownership, Xiaodong Wang